Scarica l'app Stockscreener
0.61
8.97%
-0.0601
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Relmada Therapeutics Inc Borsa (RLMD) Ultime notizie
Local Bounti (LOCL) insider files Form 144 to sell 3,500 shares - Stock Titan
Head-To-Head Contrast: Tempest Therapeutics (NASDAQ:TPST) vs. Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Shares Down 3.1% – What’s Next? - Defense World
Relmada Therapeutics (RLMD) Appoints New Chief Medical Officer | - GuruFocus
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD a - GuruFocus
Relmada Therapeutics appoints Raj Pruthi as CMO, Urology - TipRanks
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology | RLMD Stock News - GuruFocus
Top Bladder Cancer Expert Joins Relmada as CMO: Phase 3 Trial Launch Set for 2026 - Stock Titan
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology - The Manila Times
Two Sigma Investments LP Sells 63,736 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World
Two Sigma Advisers LP Reduces Holdings in Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World
Relmada Therapeutics Holds Annual Stockholders Meeting - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Lowered to Strong Sell Rating by Wall Street Zen - Defense World
RELMADA THERAPEUTICS Executives Make Significant Stock Purchases in May 2025 - TradingView
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail
Relmada Therapeutics’ Earnings Call: Promising Data Amid Financial Concerns - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Relmada Therapeutics’ Q1 2025 results miss EPS expectations - Investing.com
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... - Yahoo Finance
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights - GuruFocus
Relmada Therapeutics Reports Q1 2025 Financial Results - TipRanks
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Relmada Therapeutics to Report First Quarter 2025 Financial Resu - GuruFocus
Relmada Therapeutics (RLMD) Expected to Announce Earnings on Monday - Defense World
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - The Manila Times
Relmada Therapeutics, Inc. Announces Conference Call to Discuss Q1 2025 Financial Results and Business Progress - Nasdaq
Renaissance Technologies LLC Buys 138,625 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World
Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com
It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News
AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News
Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX
Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - EIN News
Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com
Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com
Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com
Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada
Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com
SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow
Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider
Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan
Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus
Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus
Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq
Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
2.10%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):